
Synapticure
We deliver personalized medicine for neurodegenerative patients
- Founded
- 2019
- Status
- Active
- Stage
- Early
- Team size
- 115
- Location
- Chicago, IL, USA; Remote
- Category
- Consumer Health & Wellness
- Sector
- Healthcare Services
About Synapticure
Personalized virtual clinical care is finally here for neurodegenerative diseases like Alzheimer's and related Dementias (Cognitive), Parkinson's and Huntington's (Movement), and ALS (Motor neuron). We provide a novel approach to care in these diseases, centering a patient and caregiver around a coordinator who quarterbacks patients through our full Multi-Disciplinary Care Resources to local aid, PT/OT and home health support. When you leave our clinic, it's not with a handful of paper referrals, but with our coordinators helping you book and find the best physicians, DME, trials, and even cheapest prescriptions. We are devoted to helping patients, from guidance on care and insurance to providing the full spectrum of investigational and clinical testing to improve outcomes. Synapticure was built by leading patient and caregiver advocates alongside leading clinicians, biotech executives and telemedicine executives to bring the neurodegenerative disease care and treatment experience into the 21st century, and is backed by the leading Venture funds and investors in the remote health and life sciences space.
Federal research funding
5 NIH awards totalling $5,175,078, FY2022 to FY2026.
- 3D in vitro model of genetic and sporadic FTD: accelerating novel therapeutic development
- Mature brain organoid platform for therapeutic screening for ALS/FTD
- Novel patient-derived 3D platform for detecting TDP-43 proteinopathy and associated biomarkers for ALS/FTD
Source: NIH RePORTER.
Securities filings
1 Form D filing on record, 2024.
Filed as Synapticure, Inc.
Source: SEC EDGAR. Form D reports an exempt offering; it does not confirm funds raised.
Company data compiled and maintained by Healthcare Discovery.
